Bevacizumab, a humanized anti-VEGF monoclonal antibody, is not only the most widely studied antiangiogenesis agent across distinct tumors, but also the first active targeted agent in ovarian cancer [11]. This evidence concerns the gene VEGFA and ovarian carcinoma.